(normal value in our laboratory < 210 U I-) in relation to serum gamma glutamyltranspeptidase level above 100 IU I-(normal value in our laboratory < 32 U 1'), or liver-specific alkaline phosphatase elevated. In addition to these jaundiced or cholestatic patients the following patients were included: patients with a history of two or more episodes of acute pancreatitis, patients who had continuous or recurring abdominal pain with raised serum or urine amylase levels measured at least three times, patients who had been suspected to have a pancreatic tumour or chronic pancreatitis in ultrasound or computed, tomography examination. Exclusion criteria were: age less than 15 years, pregnancy, jaundice developing in the intensive care unit, a history of recent heart surgery, insufficient cooperation, acute alcoholic pancreatitis, disseminated malignancy, parenchymal liver disease diagnosed within 2 days of admission, need for emergency surgery. One hundred and ninety-three patients were included altogether. The patients have been previously described in detail (Pasanen et al., 1992) . There were altogether 24 patients with the final diagnosis of carcinoma of the head of the pancreas and two patients with the diagnosis of carcinoma of the ampulla of Vater.
Evaluation of the results of various tumour marker studies is often problematic because of variance in the patient populations and in the cut-off values used in these studies. In many studies the sera of heterogenous populations (healthy blood donors, laboratory staff, patients with various types of cancer) have been used as reference patient material. This seems, however, unsatisfactory unless blind screening methods for the whole population are being sought. The diagnostic accuracy and cut-off values of the tumour marker tests should be tested in a relevant patient population (Roberts, 1986) . In practice -and not least for reasons of economy -we should be able to focus these tests on patient groups with a high risk of certain types of cancer. The use of receiver operating characteristic (ROC) curve analysis has gained increasing popularity among clinical investigators (Feinstein, 1985) . It makes possible comparisons of the sensitivity and specificity of different tests independently of the relative incidences of the diseases and of the cut-off level. This prospective series of 193 consecutive patients with jaundice and/or cholestasis (n = 133), and with a suspicion of chronic pancreatitis or pancreatic tumour (n = 60) offers a good opportunity for such an analysis with regard to the diagnosis of pancreatic cancer. We measured the serum values of carcinoembryonic antigen (CEA), cancer associated carboanhydrate antigens CA 50 and CA 242 in these patients, and compared them with the help of ROC curves.
Patients
The patient population of this prospective study consisted of a consecutive series of patients admitted to or attending Kuopio University Hospital during the two-and-a-half year period from the beginning of December 1985 to the end of May 1988. The limits for inclusion to the study were defined as follows: a serum bilirubin level exceeding 40 micromoles per litre (normal value in our laboratory < 17 jimol 1-'), and/or serum alkaline phosphatase level above 350 IU -(normal value in our laboratory < 210 U I-) in relation to serum gamma glutamyltranspeptidase level above 100 IU I-(normal value in our laboratory < 32 U 1'), or liver-specific alkaline phosphatase elevated. In addition to these jaundiced or cholestatic patients the following patients were included: patients with a history of two or more episodes of acute pancreatitis, patients who had continuous or recurring abdominal pain with raised serum or urine amylase levels measured at least three times, patients who had been suspected to have a pancreatic tumour or chronic pancreatitis in ultrasound or computed, tomography examination. Exclusion criteria were: age less than 15 years, pregnancy, jaundice developing in the intensive care unit, a history of recent heart surgery, insufficient cooperation, acute alcoholic pancreatitis, disseminated malignancy, parenchymal liver disease diagnosed within 2 days of admission, need for emergency surgery. One hundred and ninety-three patients were included altogether. The patients have been previously described in detail (Pasanen et al., 1992) . There were altogether 24 patients with the final diagnosis of carcinoma of the head of the pancreas and two patients with the diagnosis of carcinoma of the ampulla of Vater.
Methods
Clinical assessment, laboratory tests, and imaging methods (ultrasound, computed tomography and endoscopic retrograde cholangio-pancreatography) were performed as previously decribed (Pasanen et al., 1992) . In addition, liver biopsy was obtained or secretin-cerulein test was performed if hepatocellular disease or chronic pancreatitis was suspected. All the patients involved in the study were scheduled for re-examination 6 months after entering the study, and the clinical data of the hospital records were reviewed retrospectively after a follow-up period of 2 years. The (Feinstein, 1985) . The differences in diagnostic accuracy between the marker tests were measured by McNemar's test (Armitage & Berry, 1987) .
Results
We have previously reported the results of the CEA, CA 50 and CA 242 assays in detail (Pasanen et al., 1992 Figure 1 . The sensitivity of each marker was determined at several specificity levels. The corresponding sensitivities and actual cut-off points producing Figure 1 are given in Table I When the recommended cut-off level of 17 U ml-' was used for CA 50, one pancreatic cancer remained undiagnosed, but 100 false positive diagnoses were made (sensitivity 96.1%, specificity 58.0%). In the ROC analysis the optimal cut-off level was 137 U ml', which gave a specificity of 83.8% at the sensitivity level of 77%. Between the limits of 17 U ml' and 137 U ml' there were 40 false positive diagnoses which comprised 22 cases of choledochal stones, 15 of acute or chronic pancreatitis, and 11 of benign liver disease.
When we applied the recommended cut-off level of 20 U ml1' for CA 242, its sensitivity was 81% and specificity 79%. The sensitivity did not essentially improve even at the specificity level of 60% (Figure 1 ). In the ROC analysis, therefore, the optimal cut-off level for CA 242 was set to 21 U ml1', which gave a sensitivity of 81% at the same level of specificity. There were three false positive diagnoses between the levels of 20 U ml' and 21 U ml' in this series (U ml-') (two cases of choledochal stones and one of benign liver disease).
Discussion
The reference and the cut-off values are produced for clinicians to support clinical decision making. The selected cut-off value of a laboratory test should provide the best diagnostic performance for either ruling out or ruling in the particular disease. The ROC curve analysis is a graphic method which can be used to determine this optimal cut-off level (Feinstein, 1985) . In addition, it can be used in graphic comparison of the sensitivity and specificity of different diagnostic tests. This method has been successfully applied for comparing tumour marker tests (Eskelinen et al., 1989; Nilsson et al., 1992; Haglund et al., 1992) . During recent years various serological markers have been developed in the diagnosis of pancreatic cancer and in many studies considerably high sensitivities and specificities have been reported. Serum CEA and CA 50 are among the most intensively studied tumour markers and their role as reference markers is established (Kalser et al., 1978; Hansen et al., 1974; Lindholm et al., 1983; Jalanko et al., 1985; Masson et al., 1990; Haglund et al., 1992) . CA 242 is a novel tumour marker which has proved promising because of its high specificity (Haglund et al., 1989; Kuusela et al., 1991; Nilsson et al., 1992; Pasanen et al., 1992) . Evaluation of these marker studies is often difficult because of variance and heterogenity of the reference populations, and perhaps this is one reason why the role of these markers in pancreatic cancer is not yet clearly established. The patient population of this prospective study consists of a consecutive series of patients with jaundice and/or cholestasis (n = 133), or with suspicion of chronic pancreatitis or pancreatic tumour (n = 60), and therefore it can be regarded as a relevant reference population in the diagnosis of pancreatic cancer.
In the ROC analysis of the current study all marker tests reached considerably high sensitivities (77-81%) at the specificity level of 80%. The CA 242 test was significantly more sensitive than CEA and CA 50 at high specificity levels (>0.90), but slightly less sensitive at low specificity levels (<0.60). The CEA test and CA 50 test performed equally well at high and low specificity levels (Figure 1 ). This analysis shows that the CA 242 test has a clear advantage over CEA and CA 50 because of its higher specificity, confirming thus the results of previous studies (Haglund et al., 1989; Kuusela et al., 1991; Nilsson et al., 1992; Pasanen et al., 1992) .
The cut-off values recommended by the manufacturers for CEA (2.5 ng ml-') for CA 50 (17 U ml-'), and for CA 242
(20 U ml-') are based on healthy blood donors. When we used these levels for our patients, very high (92-96%) sensitivities were reached for CEA and CA 50, but the specificities remained low (<60%). The sensitivity of CA 242 was inferior (61.5%) to that of CEA or CA 50, but its specificity was clearly higher (79%). The ROC analysis of this study suggests that higher cut-off values for CEA and CA 50 should be used in order to optimise their use in the diagnosis of pancreatic cancer. Especially the specificity of these tests seems unacceptably low in the patients with jaundice and/or cholestasis. It has been shown in many studies that elevated CEA and CA 50 levels are seen in hepatocellular diseases and in benign biliary obstructions (Begent et al., 1984; Kalser et al., 1978; Lurie et al.,1975; Carr-Locke et al., 1980; Haglund et al., 1987) . According to this study, it would seem optimal to use a cut-off level for CEA almost two times higher (4.1 ng ml-') than what has been recommended, and an almost ten times higher level for CA 50 (137U ml-'), since they gave a sensitivity of 77% at the specificity levels of 83% and 84%, respectively. For CA 242 the optimal cut-off level would be 21 U ml-', giving the sensitivity and specificity of 81%.
In conclusion, the ROC curve analysis of this study shows that the CA 242 test has an advantage over CEA and CA 50 because of its higher specificity in the diagnosis of pancreatic cancer. In addition, it would seem reasonable to use clearly higher cut-off values than what has been recommended for CEA and CA 50 in the diagnosis of pancreatic cancer, but for CA 242 the recommended value of 20 U ml-' seems appropriate. We propose that the ROC curve analysis should always be performed when a new tumour marker test is introduced or when different tests are compared, and special emphasis should be put on the relevance of the study population.
